The current state of research for psychobiotics use in the management of psychiatric disorders–A systematic literature review
Open accessThe DOI matches its Crossref record; 89 of the 90 references it cites were found in a registry or an index.
Abstract
The need to find new therapeutic interventions in patients diagnosed with psychiatric disorders is supported by the data suggesting high rates of relapse, chronic evolution, therapeutic resistance, or lack of adherence and disability. The use of pre-, pro-, or synbiotics as add-ons in the therapeutic management of psychiatric disorders has been explored as a new way to augment the efficacy of psychotropics and to improve the chances for these patients to reach response or remission. This systematic literature review focused on the efficacy and tolerability of psychobiotics in the main categories of psychiatric disorders and it has been conducted through the most important electronic databases and clinical trial registers, using the PRISMA 2020 guidelines. The quality of primary and secondary reports was assessed using the criteria identified by the Academy of Nutrition and Diabetics. Forty-three sources, mostly of moderate and high quality, were reviewed in detail, and data regarding the efficacy and tolerability of psychobiotics was assessed. Studies exploring the effects of psychobiotics in mood disorders, anxiety disorders, schizophrenia spectrum disorders, substance use disorders, eating disorders, attention deficit hyperactivity disorder (ADHD), neurocognitive disorders, and autism spectrum disorders (ASD) were included. The overall tolerability of the interventions assessed was good, but the evidence to support their efficacy in specific psychiatric disorders was mixed. There have been identified data in favor of probiotics for patients with mood disorders, ADHD, and ASD, and also for the association of probiotics and selenium or synbiotics in patients with neurocognitive disorders. In several domains, the research is still in an early phase of development, e.g., in substance use disorders (only three preclinical studies being found) or eating disorders (one review was identified). Although no well-defined clinical recommendation could yet be formulated for a specific product in patients with psychiatric disorders, there is encouraging evidence to support further research, especially if focused on the identification of specific sub-populations that may benefit from this intervention. Several limitations regarding the research in this field should be addressed, i.e., the majority of the finalized trials are of short duration, there is an inherent heterogeneity of the psychiatric disorders, and the diversity of the explored Philae prevents the generalizability of the results from clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some of the bacteria from these and other genera, such as B. helveticus, B. longum, B. animalis, Bacillus subtilis and Enterococcus faecium, have been reported to produce or promote the synthesis of neurotransmitters in the gut18–24, consequently modulating MGBA pathways and affecting behavior25–29.”
From Exploring the impact of probiotics on adult ADHD management through a double-blind RCT (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, probiotic supplementation showed positive effects on ADHD symptoms among children, though much of the evidence comes from open trials rather than randomized controlled trials (RCTs)21.”
From Exploring the impact of probiotics on adult ADHD management through a double-blind RCT (2024) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
The pros, cons, and many unknowns of probiotics
Suez, J., Zmora, N., Segal, E., & Elinav, E. (2019) · Nature Medicine · doi:10.1038/s41591-019-0439-x · Cited by 1,398 · cited 2×
“The exact mechanisms by which psychobiotics exert their action are incompletely described, but induction of immunomodulatory mechanisms, protective effects against physiological stress, inhibition of pathogens growth, microbiome modulation, and improvement of the barrier function of the colonic epithelium have been ex…”
BackgroundPsychobiotics: A novel class of psychotropic
Dinan, T. G., Stanton, C., & Cryan, J. F. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.05.001 · Cited by 1,287
Probiotics, Prebiotics, and Synbiotics
de Vrese, M., & Schrezenmeir, J. (2008) · Advances in Biochemical Engineering/Biotechnology · doi:10.1007/10_2008_097 · Cited by 1,028 · cited 5×
“Within this review, the category of “psychobiotics” includes probiotics (bacteria), prebiotics (nondigestible oligosaccharides), and synbiotics (various combinations of the previous products) (9).”
BackgroundInfluentialThe gut microbiota in anxiety and depression—A systematic review
Simpson, C. A., Diaz-Arteche, C., Eliby, D., Schwartz, O. S., Simmons, J. G., & Cowan, C. S. M. (2021) · Clinical Psychology Review · doi:10.1016/j.cpr.2020.101943 · Cited by 912 · cited 2×
“(66) DBRCT Older adults with MCI (N = 80) Probiotics (Bifid.”
BackgroundGut Microbiota is Altered in Patients with Alzheimer’s Disease
Zhuang, Z.-Q., Shen, L.-L., Li, W.-W., Fu, X., Zeng, F., Gui, L., Lü, Y., Cai, M., Zhu, C., Tan, Y.-L., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180176 · Cited by 885 · cited 3×
“(76) Narrative Children with Probiotics (Lact.”
InfluentialAkkasheh, G., Kashani-Poor, Z., Tajabadi-Ebrahimi, M., Jafari, P., Akbari, H., Taghizadeh, M., Memarzadeh, M. R., Asemi, Z., & Esmaillzadeh, A. (2016) · Nutrition · doi:10.1016/j.nut.2015.09.003 · Cited by 767
Zheng, P., Zeng, B., Liu, M., Chen, J., Pan, J., Han, Y., Liu, Y., Cheng, K., Zhou, C., Wang, H., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau8317 · Cited by 704 · cited 1×
“The authors of the same study concluded that schizophrenia-like behaviors might be related to hypo-glutamatergic function (72).”
BackgroundGastrointestinal microbiota in children with autism in Slovakia
Tomova, A., Husarova, V., Lakatosova, S., Bakos, J., Vlkova, B., Babinska, K., & Ostatnikova, D. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.10.033 · Cited by 632 · cited 1×
“in feces of medication-free ASD children (N = 10) (59).”
BackgroundAdverse effects of antipsychotic medications.
Muench, J., & Hamer, A. M. (2010) · PubMed · Cited by 582
Kazemi, A., Noorbala, A. A., Azam, K., Eskandari, M. H., & Djafarian, K. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.04.010 · Cited by 534
Kim, C.-S., Cha, J., Sim, M., Jung, S., Chun, W. Y., Baik, H. W., & Shin, D.-M. (2021) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glaa090 · Cited by 527
The Gastrointestinal Microbiome: Alcohol Effects on the Composition of Intestinal Microbiota
Engen, P. (2015) · Alcohol Research: Current Reviews · doi:10.35946/arcr.v37.2.07 · Cited by 436
Slykerman, R. F., Hood, F., Wickens, K., Thompson, J. M. D., Barthow, C., Murphy, R., Kang, J., Rowden, J., Stone, P., Crane, J., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.09.013 · Cited by 422
Treatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
Metagenome-wide association of gut microbiome features for schizophrenia
Zhu, F., Ju, Y., Wang, W., Wang, Q., Guo, R., Ma, Q., Sun, Q., Fan, Y., Xie, Y., Yang, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15457-9 · Cited by 409 · cited 1×
“81 controls, it was observed that the first group presented differences in SCFAs, and neurotransmitters degradation or synthesis; therefore, at least some changes exist prior to the onset of the antipsychotic treatment in schizophrenia (70).”
BackgroundTamtaji, O. R., Heidari-soureshjani, R., Mirhosseini, N., Kouchaki, E., Bahmani, F., Aghadavod, E., Tajabadi-Ebrahimi, M., & Asemi, Z. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.11.034 · Cited by 398
Pärtty, A., Kalliomäki, M., Wacklin, P., Salminen, S., & Isolauri, E. (2015) · Pediatric Research · doi:10.1038/pr.2015.51 · Cited by 397
Brain–gut–microbiota axis in depression: A historical overview and future directions
Chang, L., Wei, Y., & Hashimoto, K. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.02.004 · Cited by 377
The role of probiotics in children with autism spectrum disorder: A prospective, open-label study
Shaaban, S. Y., El Gendy, Y. G., Mehanna, N. S., El-Senousy, W. M., El-Feki, H. S. A., Saad, K., & El-Asheer, O. M. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1347746 · Cited by 374
Romijn, A. R., Rucklidge, J. J., Kuijer, R. G., & Frampton, C. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416686694 · Cited by 323 · cited 3×
“A trial that enrolled 79 participants with mood symptoms selfevaluated as being of at least moderate severity, randomly assigned to a probiotic (Lactobacillus helveticus and Bifidobacterium longum) or an inactive compound, in a double-blind, 8 weeks trial (26).”
BackgroundInfluentialChahwan, B., Kwan, S., Isik, A., van Hemert, S., Burke, C., & Roberts, L. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.097 · Cited by 256
Oxidative Stress and Dementia in Alzheimer’s Patients: Effects of Synbiotic Supplementation
Ton, A. M. M., Campagnaro, B. P., Alves, G. A., Aires, R., Côco, L. Z., Arpini, C. M., Guerra e Oliveira, T., Campos-Toimil, M., Meyrelles, S. S., Pereira, T. M. C., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2638703 · Cited by 217
Chong, H. X., Yusoff, N. A. A., Hor, Y.-Y., Lew, L.-C., Jaafar, M. H., Choi, S.-B., Yusoff, M. S. B., Wahid, N., Abdullah, M. F. I. L., Zakaria, N., et al. (2019) · Beneficial Microbes · doi:10.3920/bm2018.0135 · Cited by 206
Xiao, J., Katsumata, N., Bernier, F., Ohno, K., Yamauchi, Y., Odamaki, T., Yoshikawa, K., Ito, K., & Kaneko, T. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200488 · Cited by 203
The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse
Morgan, A. P., Crowley, J. J., Nonneman, R. J., Quackenbush, C. R., Miller, C. N., Ryan, A. K., Bogue, M. A., Paredes, S. H., Yourstone, S., Carroll, I. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115225 · Cited by 197 · cited 3×
“, Enterococcus faecalis, Escherichia coli) (64).”
BackgroundInfluentialKobayashi, Y., Kuhara, T., Oki, M., & Xiao, J.-Z. (2019) · Beneficial Microbes · doi:10.3920/bm2018.0170 · Cited by 195
Role of diet and its effects on the gut microbiome in the pathophysiology of mental disorders
Horn, J., Mayer, D. E., Chen, S., & Mayer, E. A. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01922-0 · Cited by 193 · cited 4×
“Anti-inflammatory effects mediated by the microbial metabolites of dietary fibers and polyphenols are considered responsible for the benefits of diet on GM (87).”
BackgroundInfluentialMiyaoka, T., Kanayama, M., Wake, R., Hashioka, S., Hayashida, M., Nagahama, M., Okazaki, S., Yamashita, S., Miura, S., Miki, H., et al. (2018) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000299 · Cited by 186
Del Toro-Barbosa, M., Hurtado-Romero, A., Garcia-Amezquita, L. E., & García-Cayuela, T. (2020) · Nutrients · doi:10.3390/nu12123896 · Cited by 183
Dash, S., Syed, Y. A., & Khan, M. R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.880544 · Cited by 171 · cited 2×
“Neuroinflammation in ADHD patients, abnormal activation of microglia, and altered proportion between pro- and anti-inflammatory cytokines may alter the maturation of the prefrontal cortex and the neurotransmission systems, increasing the risk for ADHD onset (86).”
BackgroundDickerson, F. B., Stallings, C., Origoni, A., Katsafanas, E., Savage, C. L. G., Schweinfurth, L. A. B., Goga, J., Khushalani, S., & Yolken, R. H. (2014) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.13m01579 · Cited by 166
Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients
Ghaderi, A., Banafshe, H. R., Mirhosseini, N., Moradi, M., Karimi, M.-A., Mehrzad, F., Bahmani, F., & Asemi, Z. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2059-x · Cited by 166 · cited 1×
“placebo in 60 patients with chronic schizophrenia, administered for 12 weeks, were compared in a randomized, placebo-controlled trial (42).”
MethodPsychotropics and the Microbiome: a Chamber of Secrets…
Cussotto, S., Clarke, G., Dinan, T. G., & Cryan, J. F. (2019) · Psychopharmacology · doi:10.1007/s00213-019-5185-8 · Cited by 163
The intestinal microbiota and metabolites in patients with anorexia nervosa
Procházková, P., Roubalová, R., Dvořák, J., Kreisinger, J., Hill, M., Tlaskalová‐Hogenová, H., Tomášová, P., Pelantová, H., Cermakova, M., Kuzma, M., et al. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1902771 · Cited by 163 · cited 4×
“Lower levels of serotonin, GABA, dopamine, butyrate, and acetate in AN patients’ feces were detected when compared to healthy controls (81).”
BackgroundInfluentialParracho, H. M. R. T., Gibson, G. R., Knott, F., Bosscher, D., Kleerebezem, M., & McCartney, A. L. (2010) · International Journal of Probiotics and Prebiotics · Cited by 162
Barengolts, E. I. (2016) · Endocrine Practice · doi:10.4158/ep151157.ra · Cited by 161
Mechanistic Insights into the Link between Gut Dysbiosis and Major Depression: An Extensive Review
Sonali, S., Ray, B., Ahmed Tousif, H., Rathipriya, A. G., Sunanda, T., Mahalakshmi, A. M., Rungratanawanich, W., Essa, M. M., Qoronfleh, M. W., Chidambaram, S. B., et al. (2022) · Cells · doi:10.3390/cells11081362 · Cited by 156
Tomasik, J., Yolken, R. H., Bahn, S., & Dickerson, F. B. (2015) · Biomarker Insights · doi:10.4137/bmi.s22007 · Cited by 152
Okubo, R., Koga, M., Katsumata, N., Odamaki, T., Matsuyama, S., Oka, M., Narita, H., Hashimoto, N., Kusumi, I., Xiao, J., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.11.011 · Cited by 149
Tan, Q., Orsso, C. E., Deehan, E. C., Kung, J. Y. C., Tun, H. M., Wine, E., Madsen, K. L., Zwaigenbaum, L., & Haqq, A. M. (2021) · Autism Research · doi:10.1002/aur.2560 · Cited by 145
Zhou, Y., Wang, Y., Quan, M., Zhao, H., & Jia, J. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201497 · Cited by 136 · cited 1×
“Another study with a similar methodology reported a higher concentration of Bifidobacterium, Sphingomonas, Lactobacillus, and Blautia in patients with neurocognitive disorders, while Odoribacter, Anaerobacterium, and Papillibacter were reduced (77).”
ResultHaghighat, N., Rajabi, S., & Mohammadshahi, M. (2021) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1646975 · Cited by 133
The Microbiome-Gut-Brain Axis and Resilience to Developing Anxiety or Depression under Stress
Bear, T., Dalziel, J., Coad, J., Roy, N., Butts, C., & Gopal, P. (2021) · Microorganisms · doi:10.3390/microorganisms9040723 · Cited by 126
Grossi, E., Melli, S., Dunca, D., & Terruzzi, V. (2016) · SAGE Open Medical Case Reports · doi:10.1177/2050313x16666231 · Cited by 113
Munawar, N., Ahsan, K., Muhammad, K., Ahmad, A., Anwar, M. A., Shah, I., Ameri, A. A., & Mughairbi, F. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147671 · Cited by 110 · cited 11×
“Therapeutic approaches to SSD are limited to antipsychotics with different metabolic or neurological adverse events, while Frontiers in Psychiatry 15 frontiersin.org fpsyt-14-1074736 February 21, 2023 Time: 16:36 # 16 Vasiliu 10.3389/fpsyt.2023.1074736 psychotherapy and other types of explored interventions have very…”
BackgroundInfluentialProbiotics for dementia: a systematic review and meta-analysis of randomized controlled trials
Krüger, J. F., Hillesheim, E., Pereira, A. C. S. N., Camargo, C. Q., & Rabito, E. I. (2021) · Nutrition Reviews · doi:10.1093/nutrit/nuaa037 · Cited by 109
Knuesel, T., & Mohajeri, M. H. (2021) · Nutrients · doi:10.3390/nu14010037 · Cited by 109
Tran, N., Zhebrak, M., Yacoub, C., Pelletier, J., & Hawley, D. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.043 · Cited by 104
Current Status of Evidence for a New Diagnosis: Food Addiction-A Literature Review
Vasiliu, O. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.824936 · Cited by 104
Self-citationBaldi, S., Mundula, T., Nannini, G., & Amedei, A. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i39.6715 · Cited by 98
Tremblay, A., Lingrand, L., Maillard, M., Feuz, B., & Tompkins, T. A. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110142 · Cited by 95
From probiotics to psychobiotics - the gut-brain axis in psychiatric disorders
Zagórska, A., Marcinkowska, M., Jamrozik, M., Wiśniowska, B., & Paśko, P. (2020) · Beneficial Microbes · doi:10.3920/bm2020.0063 · Cited by 92 · cited 1×
“placebo, but not in the case of schizophrenia, stress, and anxiety (90).”
BackgroundMicrobiome-Gut-Brain Axis: Probiotics and Their Association With Depression
Cepeda, M. S., Katz, E. G., & Blacketer, C. (2017) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.15120410 · Cited by 89
Vaghef-Mehrabany, E., Maleki, V., Behrooz, M., Ranjbar, F., & Ebrahimi-Mameghani, M. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2019.06.004 · Cited by 89 · cited 2×
“The need for more well-designed trials focused on specific probiotic strains, inter-individual GM variations, and more homogenous phenotypes of psychiatric disorders has been emphasized by other authors exploring this topic (91, 92).”
BackgroundResultPsychobiotics as treatment for anxiety, depression, and related symptoms: a systematic review
Smith, K. S., Greene, M. W., Babu, J. R., & Frugé, A. D. (2019) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1701220 · Cited by 88
Eskandarzadeh, S., Effatpanah, M., Khosravi-Darani, K., Askari, R., Hosseini, A. F., Reisian, M., & Jazayeri, S. (2021) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1598669 · Cited by 80
Role of Brain-Gut-Microbiota Axis in Depression: Emerging Therapeutic Avenues
Bhatt, S., Kanoujia, J., Mohana Lakshmi, S., Patil, C., Gupta, G., Chellappan, D. K., & Dua, K. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220329140804 · Cited by 76
Patusco, R., & Ziegler, J. (2018) · Advances in Nutrition · doi:10.1093/advances/nmy031 · Cited by 75
The Gut Microbiome in Schizophrenia and the Potential Benefits of Prebiotic and Probiotic Treatment
Liu, J. C. W., Gorbovskaya, I., Hahn, M., & Müller, D. J. (2021) · Nutrients · doi:10.3390/nu13041152 · Cited by 74
Gualtieri, P., Marchetti, M., Cioccoloni, G., LORENZO, A. D., Romano, L., Cammarano, A., Colica, C., Condò, R., & Renzo, L. D. (2020) · Mediators of Inflammation · doi:10.1155/2020/2346126 · Cited by 73
Skott, E., Yang, L. L., Stiernborg, M., Söderström, Å., Rȕegg, J., Schalling, M., Forsell, Y., Giacobini, M., & Lavebratt, C. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.05.056 · Cited by 73 · cited 4×
“In children, this product reduced the overall severity of autism symptoms and the sub-domains of ASD behaviors (60).”
BackgroundMethodInfluentialTomizawa, Y., Kurokawa, S., Ishii, D., Miyaho, K., Ishii, C., Sanada, K., Fukuda, S., Mimura, M., & Kishimoto, T. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa070 · Cited by 72
Browne, P. D., Bolte, A. C., der Vaart, I. B.-V., Claassen, E., & de Weerth, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-81204-9 · Cited by 71
Chiu, W., Huang, Y.-L., Chen, Y.-L., Peng, H.-C., Liao, W.-H., Chuang, H.-L., Chen, J., & Yang, S. (2015) · Food & Function · doi:10.1039/c5fo00104h · Cited by 66 · cited 1×
“Another team of researchers demonstrated on male Wistar rats receiving either a normal liquid diet ± synbiotic or an ethanol liquid diet ± synbiotic supplementation for 3 months, that the addition of a synbiotic may reduce the plasma endotoxin, hepatic triglyceride, and TNF-α levels, and raise the hepatic IL-10 concen…”
BackgroundDong, Z., Shen, X., Hao, Y., Li, J., Li, H., Xu, H., Yin, L., & Kuang, W. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.651536 · Cited by 66
Leyrolle, Q., Cserjesi, R., Mulders, M. D. G. H., Zamariola, G., Hiel, S., Gianfrancesco, M. A., Rodriguez, J., Portheault, D., Amadieu, C., Leclercq, S., et al. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2020.09.025 · Cited by 65
A Designer Synbiotic Attenuates Chronic-Binge Ethanol-Induced Gut-Liver Injury in Mice
Roychowdhury, S., Glueck, B., Han, Y., Mohammad, M. A., & Cresci, G. A. M. (2019) · Nutrients · doi:10.3390/nu11010097 · Cited by 62
Desai, V., Kozyrskyj, A. L., Lau, S., Sanni, O. B., Dennett, L., Walter, J., & Ospina, M. B. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.622181 · Cited by 60
Wang, L.-J., Yang, C.-Y., Kuo, H.-C., Chou, W.-J., Tsai, C.-S., & Lee, S.-Y. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020227 · Cited by 58 · cited 18×
“ADHD symptoms were subjectively determined.”
BackgroundMethodInfluentialLouzada, E. R., & Ribeiro, S. M. L. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2018.1477349 · Cited by 57
A Systematic Review of the Microbiome in Children With Neurodevelopmental Disorders
Lacorte, E., Gervasi, G., Bacigalupo, I., Vanacore, N., Raucci, U., & Parisi, P. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00727 · Cited by 57 · cited 2×
“Attention deficit hyperactivity disorder in children has been associated with a higher representation of Bacteroidaceae and Neisseriaceae, which may cause a significant decrease in GM heterogeneity (85).”
BackgroundTarget Dysbiosis of Gut Microbes as a Future Therapeutic Manipulation in Alzheimer’s Disease
Zhu, F., Li, C., Chu, F., Tian, X., & Zhu, J. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.544235 · Cited by 57 · cited 1×
“Changes in the GM can be considered between the potential pathogenic causes for the onset of neurocognitive disorders, for example, Alzheimer’s dementia (75).”
BackgroundHofmeister, M., Clement, F., Patten, S., Li, J., Dowsett, L. E., Farkas, B., Mastikhina, L., Egunsola, O., Diaz, R., Cooke, N. C. A., et al. (2021) · CMAJ Open · doi:10.9778/cmajo.20200283 · Cited by 53
Minichino, A., Brondino, N., Solmi, M., Del Giovane, C., Fusar-Poli, P., Burnet, P., Cipriani, A., & Lennox, B. R. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.02.012 · Cited by 50
Cooke, M. B., Catchlove, S. J., & Tooley, K. L. (2022) · Nutrients · doi:10.3390/nu14214623 · Cited by 49
Gut microbiota and microbiome in schizophrenia
Samochowiec, J., & Misiak, B. (2021) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000733 · Cited by 48 · cited 1×
“GM in schizophrenia may be associated with neurostructural changes, psychopathology severity, subclinical inflammatory processes, and higher cardiovascular risk (71).”
BackgroundShahrbabaki, M. E., Sabouri, S., Sabahi, A., Barfeh, D., Divsalar, P., Divsalar, P., Esmailzadeh, M., & Ahmadi, A. (2020) · Iranian Journal of Psychiatry · doi:10.18502/ijps.v15i1.2435 · Cited by 46
Vasiliu, O. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2124071 · Cited by 34 · cited 1×
“Eating disorders have been associated with high risks for overall health status, quality of life, and general functionality (4, 79).”
BackgroundSelf-citationAgenagnew, L., & Kassaw, C. (2020) · Journal of Psychosocial Rehabilitation and Mental Health · doi:10.1007/s40737-020-00176-7 · Cited by 33
Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia
Munawar, N., Ahmad, A., Anwar, M. A., & Muhammad, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052625 · Cited by 32 · cited 12×
“Therapeutic approaches to SSD are limited to antipsychotics with different metabolic or neurological adverse events, while Frontiers in Psychiatry 15 frontiersin.org fpsyt-14-1074736 February 21, 2023 Time: 16:36 # 16 Vasiliu 10.3389/fpsyt.2023.1074736 psychotherapy and other types of explored interventions have very…”
BackgroundInfluentialMitchell, L. K., & Davies, P. S. W. (2021) · European Journal of Clinical Nutrition · doi:10.1038/s41430-021-01027-9 · Cited by 30
Han, Y., Glueck, B., Shapiro, D. B., Miller, A. W., Roychowdhury, S., & Cresci, G. (2020) · Nutrients · doi:10.3390/nu12020373 · Cited by 29 · cited 2×
“The synbiotic administered in mice exposed to alcohol use reduced the negative effects on the GM and liver endothelial barrier integrity (43).”
BackgroundChoi, B. S.-Y., Daoust, L., Pilon, G., Marette, A., & Tremblay, A. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-0618-3 · Cited by 21
Current Trends and Perspectives in the Immune Therapy for Substance Use Disorders
Vasiliu, O. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.882491 · Cited by 20 · cited 1×
“Most of the data regarding this subject are derived from animal studies, which showed a connection between chronic alcohol use and increased oxidative stress, higher intestinal permeability to different bacteriaproduced toxic factors, and the onset of alcoholic hepatitis (2, 74).”
BackgroundSelf-citationAnorexia nervosa and gut microbiome: implications for weight change and novel treatments
Wei, Y., Peng, S., Lian, C., Kang, Q., & Chen, J. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2056017 · Cited by 18
Vasiliu, O. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.786171 · Cited by 15
Self-citationVasiliu, O. (2020) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2020.123.1.1 · Cited by 11 · cited 2×
“psychotherapy and other types of explored interventions have very limited benefits (3, 67, 68).”
BackgroundSelf-citationCauli, O., Guevara-González, J., Guevara-Campos, J., & González, L. (2021) · Current Clinical Pharmacology · doi:10.2174/2772432816666210805141257 · Cited by 9 · cited 1×
“Administration of probiotics containing Lactobacillus and Bifidobacteria strains may favor gastrointestinal and behavioral symptoms in ASD patients with gastrointestinal disturbances (84).”
Background
Research works printed but not linked: 2
- Berkman N Lohr K Ansari M McDonagh M Balk E Whitlock E Grading the Strength of a Body of Evidence when Assessing Health Care Interventions for the Effective Health Care Program of the Agency for Healthcare Research and Quality: An Update. Methods guide for Comparative Effectiveness Reviews. (2013). Available online at: www.effectivehealthcare.ahrq.gov/reports/final.cfm (accessed August 20, 2022). 24404627
- Owens D Lohr K Atkins D Treadwell JR Reston JT Bass EB Grading the Strength of a Body of Evidence When Comparing Medical Interventions. In: Agency for Healthcare Research and Quality. Methods Guide for Comparative Effectiveness Reviews [posted July 2009]. (2022). Available online at: https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-grading-strength_methods.pdf (accessed August 20, 2022). 21433399
Cited by
Mosquera, F. E. C., Martinez, S. L., & Liscano, Y. (2024) · Nutrients · doi:10.3390/nu16091352 · Cited by 88
“Future research should focus on standardizing psychobiotic formulations and exploring their synergistic effects with conventional antidepressants to fully harness their therapeutic potential [14,24,96].”
BackgroundHuman Gut Microbiota for Diagnosis and Treatment of Depression
Averina, O. V., Poluektova, E. U., Zorkina, Y., Kovtun, A. S., & Даниленко, В. Н. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115782 · Cited by 59
Slykerman, R. F., Davies, N., Vlčková, K., O’Riordan, K. J., Bassett, S. A., Dekker, J., Schellekens, H., Hyland, N. P., Clarke, G. A., & Patterson, E. (2025) · Microbial Biotechnology · doi:10.1111/1751-7915.70079 · Cited by 50
Probiotics: Bridging the interplay of a healthy gut and psychoneurological well‐being
Meher, A. K., Acharya, B., & Sahu, P. K. (2024) · Food Bioengineering · doi:10.1002/fbe2.12081 · Cited by 42
Wang, L., Tsai, C., Chou, W., Kuo, H., Huang, Y., Lee, S.-Y., Dai, H.-Y., Yang, C.-Y., Li, C.-J., & Yeh, Y. (2024) · Nutrients · doi:10.3390/nu16142260 · Cited by 35
Metadata
- Authors
- Vasiliu, O.
- Affiliations
- Spitalul Universitar de Urgenţă Militar Central Dr. Carol Davila (RO)
- Corresponding author
- Vasiliu, Octavian
- ORCID
- Vasiliu, Octavian
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2023-02-23
- Volume
- 14
- Pages
- 1074736-1074736
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC9996157
- OpenAlex
- W4321595729
- Cited by
- 42
- References
- 90
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 12 · 2023: 8
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- psychobiotics, probiotics, synbiotics, mental illness, mood disorders, anxiety disorders, schizophrenia spectrum disorders, substance use disorders, eating disorders, attention deficit hyperactivity disorder, autism spectrum disorder, neurocognitive disorders, selenium, tolerability, efficacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.